Abstract
Atrial fibrillation is a prominent cause of morbidity and mortality in developed countries. Current treatment strategies center on controlling heart rate while allowing fibrillation to persist or targeting fibrillation primarily and attempting to maintain sinus rhythm. Pharmacological therapies are largely successful for rate control, although mild toxicities are common. Rhythm control strategies are often unsuccessful, leaving patients in atrial fibrillation despite attempts to maintain sinus rhythm. This review will discuss novel biological strategies that are currently under development and may eventually have impact on the management of atrial fibrillation.
| Original language | English |
|---|---|
| Pages (from-to) | 222-227 |
| Number of pages | 6 |
| Journal | Journal of Cardiovascular Pharmacology |
| Volume | 52 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 Sep 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Arrhythmia
- Atrial fibrillation
- Atrioventricular node
- Cell therapy
- Gene therapy
- Heart
ASJC Scopus subject areas
- Pharmacology
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Biological therapies for atrial fibrillation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver